Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab

Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab

Breast cancer is the most common cancer among the female population, and its prevalence is increasing worldwide. Trastuzumab (Herceptin) therapy improves prognosis in HER2 positive patients, but Heart Failure (HF) is one of its known complications. In this study, we aimed to assess the potential ben...

Full description

Bibliographic Details
Main Authors: Alborz Sherafati, Maryam Mehrpooya, Roya Sattarzadeh Badkoubeh, Farnoosh Larti, Farhad Shahi, Mehrzad Mirzania, Mohsen Esfandbod, Mohammad Saadat, Massoud Ghasemi, Jeyran Zebardast
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2019-05-01
Series:Acta Medica Iranica
Subjects:
Breast cancer
Trastuzumab
Carvedilol
Cardiomyopathy
Online Access:http://acta.tums.ac.ir/index.php/acta/article/view/7312

Internet

http://acta.tums.ac.ir/index.php/acta/article/view/7312

Similar Items